Xinlitai announced that recently, the clinical trial application for SAL0145 injection, an innovative drug independently developed by the company was accepted. SAL0145 is a siRNA drug developed by the company with independent intellectual property rights. The application submitted by the company is a clinical trial application for SAL0145 for the treatment of MASH.

Zhitongcaijing · 4d ago
Xinlitai announced that recently, the clinical trial application for SAL0145 injection, an innovative drug independently developed by the company was accepted. SAL0145 is a siRNA drug developed by the company with independent intellectual property rights. The application submitted by the company is a clinical trial application for SAL0145 for the treatment of MASH.